DorsaVi (ASX: DVL) Acquires Cutting-Edge Neuromorphic IP to Power Next-Gen Robotics and Wearable Intelligence

Key Highlights:

• DorsaVi secures exclusive neuromorphic Processing-in-Memory (PIM) technology portfolio from Israel’s Technion, led by Professor Shahar Kvatinsky, a global pioneer in hardware-based AI.
   
• The acquisition enables self-learning biosensors and autonomous robotic control, bringing adaptive intelligence to edge devices.
   
• Positions DorsaVi in the fast-growing US$20 billion neuromorphic computing market forecast by 2030.
   
• Executive Chairman Gernot Abl transitions to a full-time role to lead the strategic execution.
   
• Stock up 12% to $0.056, marking a 366% one-year gain, with a market cap of $63.02 million.
   

DorsaVi Ltd (ASX: DVL) has announced the acquisition of a transformational neuromorphic technology portfolio that positions the Australian wearables and motion-analysis company at the forefront of next-generation AI-enabled robotics and biosensing systems.

The exclusive intellectual property, licensed from Technion – Israel Institute of Technology, introduces a Processing-in-Memory (PIM) architecture that fuses computation and memory within a single intelligent substrate. The breakthrough allows DorsaVi’s FDA-cleared sensors and robotics interfaces to sense, learn, and react locally, eliminating cloud latency and energy inefficiency.

This strategic acquisition marks DorsaVi’s entry into the rapidly expanding neuromorphic computing industry, a market expected to grow from US$5.3 billion in 2023 to over US$20 billion by 2030, according to IBM research.

Transforming DorsaVi’s Biosensor and Robotics Ecosystem

Through this acquisition, DorsaVi gains access to dual-layer neuromorphic architecture comprising a Reflex Engine and an Adaptive Interface Layer.

• The Reflex Engine performs in-memory learning and inference, enabling reflex-speed responses and on-device adaptation.
   
• The Adaptive Interface Layer delivers noise-resilient, self-calibrating signal capture, improving real-time actuation and accuracy across complex environments.

This integration allows DorsaVi’s existing biosensors and motion-analysis platforms to transition from reactive data collectors to self-learning intelligent nodes that can interpret muscle activity, gait, and motion in real time.

The company says this development could redefine performance in prosthetics, exosuits, industrial robotics, and healthcare wearables.

Bringing “Brain-Like” Intelligence to Hardware

The neuromorphic system draws inspiration from the human brain’s efficiency, which performs trillions of operations using just 20 watts of power. In contrast, conventional CPUs and GPUs require constant data shuttling between processor and memory, creating delays and heavy energy demand.

DorsaVi’s neuromorphic PIM technology mimics biological synapses, where memory and computation coexist. This design allows each node to sense, remember, and act independently, enabling real-time, low-power decision-making — critical for wearable and industrial applications.

The technology is expected to deliver:

• Cleaner inputs with less power consumption, thanks to adaptive converters.
   
• Faster control loops, improving motion calibration and haptic feedback.
   
• Privacy-preserving intelligence, since most computation occurs on-device.
  
   

Practical Applications: From Rehab to Robotics

According to DorsaVi, the newly acquired IP unlocks applications across biomedical, ergonomic, and robotics markets:

• Rehabilitation & Clinical Use – Wearables can now detect anomalies and provide personalised movement feedback in real time, enabling clinicians to monitor patients without streaming sensitive data.
   
• Industrial Safety – Motion classifiers can trigger reflex-grade alerts for hazardous movements, improving workplace ergonomics and safety compliance.
   
• Prosthetics & Robotics – Adaptive controllers will allow real-time torque adjustments, self-tuning grip mechanisms, and context-aware motion patterns for assistive devices.
  
   

“By combining neuromorphic processing with adaptive interfaces, we are enabling machines and wearables that don’t just measure — they learn and act in real time,” said Gernot Abl, DorsaVi’s Executive Chairman. “This acquisition takes DorsaVi from reactive analytics to self-adapting, intelligent systems at the edge.”

Strategic Leadership Shift

Coinciding with this acquisition, DorsaVi announced that Gernot Abl has transitioned from Non-Executive Chairman to Executive Chairman, taking a more active role in driving the company’s strategic expansion.

The board stated that Mr. Abl’s increased involvement reflects the importance of executing DorsaVi’s technology roadmap and capital markets initiatives.

Abl’s remuneration includes $180,000 per annum plus performance-based rights, tied to share price milestones of $0.10, $0.15, and $0.20 VWAP targets within the next 36 months.

Market Reaction and Outlook

Investors responded positively to the announcement, sending DorsaVi shares up 12% to $0.056 by midday Wednesday, with trading volume exceeding 26.5 million shares. The stock has surged over 360% in the past year, reflecting growing confidence in the company’s transformation from a motion analytics firm into an AI-driven edge-computing innovator.

Analysts suggest the neuromorphic IP acquisition could position DorsaVi as a niche Australian deep-tech player in a field dominated by global giants such as IBM and Intel.

“Processing-in-Memory is the holy grail for energy-efficient AI,” said an industry analyst. “If DorsaVi successfully embeds this into its biosensor stack, it can deliver intelligent, reflexive devices that process data as fast as the brain.”

With partnerships in healthcare, industrial safety, and sports science, the company expects the new IP to unlock cross-sector product development opportunities and enhance its global commercial footprint.

Market and Transaction Overview

Under the agreement, DorsaVi will issue 80 million fully paid ordinary shares to Technion Research & Development Foundation and Neurofabrica Pty Ltd, subject to shareholder approval. The vendors will also receive staged reimbursement payments totalling US$275,000 over 24 months.

The transaction gives DorsaVi an exclusive, worldwide licence to the neuromorphic IP, covering both Processing-in-Memory (PIM) and Adaptive Interface Layer technologies.

Company Overview

DorsaVi Ltd is a Melbourne-based company specialising in wearable motion analysis and biometric sensing technologies for clinical, occupational, and sports applications.

Its solutions are used by global clients including London Underground, Boeing, Caterpillar, Woolworths, Toyota, and BHP Billiton, providing objective data to prevent injuries and optimise human performance.

The company’s flagship ViMove+ platform, approved by the U.S. FDA, enables clinicians to track patient biomechanics outside the lab — a growing market segment aligned with the rise of remote care and AI-driven health monitoring.

Investor Takeaways

✅ Strategic Leap into AI Hardware:

DorsaVi’s neuromorphic acquisition moves it from motion tracking to intelligent, self-learning biosensors and robotics systems.

✅ Strong Market Momentum:

Stock up 12% to $0.056 with a 366% annual return, supported by a $63M market cap and high trading volume.

✅ Positioned for Growth in US$20Bn Market:

Exclusive global rights to PIM-based IP position DorsaVi within the booming neuromorphic computing industry.